What is CBGV?
Cannabigerovarin, or CBGV, is a non-psychoactive cannabinoid acid. As a derivative of cannabigerol, it is part of the CBG class.
This cannabinoid shows much therapeutic potential. As a derivative of CBG, it is theorized it could potentially benefit the human body in similar ways. Additionally, research into CBGV shows that it may potentiate the effects of other cannabinoids as they interact with the CB1 and CB2 receptors of the endocannabinoid system.
Studies on CBGV
Studies show that CBGV may boost the CBD metabolism in the body, increasing the potential benefits of that cannabinoid. It also could mitigate the intoxicating effects of THC, which is helpful for people utilizing the medicinal qualities of THC who want to lessen the psychotropic effects. In general, CBGV may have a potentiating effect on any cannabinoids interacting with the endocannabinoid system. Additional studies show that CBGV has analgesic (painkilling) and anti-inflammatory properties, making it an effective treatment for conditions like fibromyalgia and arthritis.
Many cannabinoids show great promise as having anti-cancer properties, and CBGV shows potential here too. Research at the University of St George's London showed that the studied cannabinoids could interfere with the development of cancerous cells. CBGV has enormous potential for therapeutic usage, but of course, more research is needed.